{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:17:11Z","timestamp":1790997431040,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3500100"],"award-info":[{"award-number":["2022YFC3500100"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014717","name":"Youth Science Fund Project","doi-asserted-by":"publisher","award":["82222075"],"award-info":[{"award-number":["82222075"]}],"id":[{"id":"10.13039\/100014717","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010618","name":"Guangzhou University of Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010618","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U24A20800"],"award-info":[{"award-number":["U24A20800"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82230126"],"award-info":[{"award-number":["82230126"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2023ZD0502600"],"award-info":[{"award-number":["2023ZD0502600"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jare.2025.04.029","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T18:26:45Z","timestamp":1745087205000},"page":"1045-1062","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Resibufogenin protects against atherosclerosis in ApoE-\/- mice through blocking NLRP3 inflammasome assembly"],"prefix":"10.1016","volume":"80","author":[{"given":"Chen","family":"Xiaoyang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Yijun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhai","family":"Chenguang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Du","family":"Wanying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zijun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Xuegong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jare.2025.04.029_b0005","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jacc.2022.08.754","volume":"81","author":"Birtcher","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jare.2025.04.029_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2022.100335","article-title":"Atherosclerotic cardiovascular disease risk assessment: an American society for preventive cardiology clinical practice statement","volume":"10","author":"Wong","year":"2022","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.jare.2025.04.029_b0015","article-title":"Challenges and advances in the management of inflammation in atherosclerosis","author":"Xing","year":"2024","journal-title":"J Adv Res"},{"key":"10.1016\/j.jare.2025.04.029_b0020","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/s41569-021-00629-x","article-title":"Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis","volume":"19","author":"Chen","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jare.2025.04.029_b0025","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1001\/jamacardio.2022.0987","article-title":"Lipoprotein(a) and its significance in cardiovascular disease: a review","volume":"7","author":"Duarte Lau","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jare.2025.04.029_b0030","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41392-022-00955-7","article-title":"Inflammation and atherosclerosis: signaling pathways and therapeutic intervention","volume":"7","author":"Kong","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jare.2025.04.029_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2024.07.001","article-title":"Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias\u2013a report from the European society of cardiology cardiovascular round table","author":"Mach","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jare.2025.04.029_b0040","unstructured":"Editorial Committee of the Chinese Journal of Cardiovascular Disease (Online Edition). Expert consensus on atherosclerotic plaque screening and clinical management [J\/OL] Chinese Journal of Cardiovascular Disease (Online Edition), 2022, 5: e1000123(2022\u201108\u201113). doi:10.3760\/cma.j.cn116031.2022.1000123."},{"key":"10.1016\/j.jare.2025.04.029_b0045","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.jacc.2024.03.377","article-title":"Limb outcomes with ticagrelor plus aspirin in patients with diabetes mellitus and atherosclerosis","volume":"83","author":"Bonaca","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jare.2025.04.029_b0050","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/CIRCRESAHA.120.315937","article-title":"Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease","volume":"126","author":"Abbate","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.jare.2025.04.029_b0055","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1021\/acs.jmedchem.0c01924","article-title":"Development of novel tetrahydroquinoline inhibitors of NLRP3 Inflammasome for potential treatment of DSS-induced mouse colitis","volume":"64","author":"Dai","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.jare.2025.04.029_b0060","first-page":"61","article-title":"Inflammasome activation mediated by oxidised low-density lipoprotein in patients with sleep apnoea and early subclinical atherosclerosis","author":"D\u00edaz-Garc\u00eda","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jare.2025.04.029_b0065","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.autrev.2018.01.021","article-title":"Inflammation and atherosclerosis: cardiovascular evaluation in patients with autoimmune diseases","volume":"17","author":"Esc\u00e1rcega","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jare.2025.04.029_b0070","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1161\/CIRCRESAHA.118.311362","article-title":"NLRP3 inflammasome and the IL-1 pathway in atherosclerosis","volume":"122","author":"Grebe","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.jare.2025.04.029_b0075","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1038\/s41423-021-00740-6","article-title":"NLRP3 inflammasome activation and cell death","volume":"18","author":"Huang","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jare.2025.04.029_b0080","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s41590-021-00886-5","article-title":"NLRP3 inflammasome in cancer and metabolic diseases","volume":"22","author":"Sharma","year":"2021","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jare.2025.04.029_b0085","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41569-023-00946-3","article-title":"The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases","volume":"21","author":"Toldo","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jare.2025.04.029_b0090","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev-immunol-081022-021207","article-title":"Structural mechanisms of NLRP3 inflammasome assembly and activation","volume":"41","author":"Fu","year":"2023","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jare.2025.04.029_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2024.117969","article-title":"ZeXieYin formula alleviates atherosclerosis by inhibiting the MAPK\/NF-\u03baB signaling pathway in APOE-\/- mice to attenuate vascular inflammation and increase plaque stability","volume":"327","author":"Huang","year":"2024","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.jare.2025.04.029_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.155002","article-title":"Salvianolic acid B inhibits atherosclerosis and TNF-\u03b1-induced inflammation by regulating NF-\u03baB\/NLRP3 signaling pathway","volume":"119","author":"Zhao","year":"2023","journal-title":"Phytomedicine"},{"key":"10.1016\/j.jare.2025.04.029_b0105","unstructured":"F L, WX Z, Y Y, CJ G. Research progress on the regulatory mechanism of NLRP3 inflammasome activation. Biomedical transformation 2024; 5: 2-11+35."},{"key":"10.1016\/j.jare.2025.04.029_b0110","article-title":"Blocking TRPV4 ameliorates osteoarthritis by inhibiting M1 Macrophage polarization via the ROS\/NLRP3 signaling pathway","volume":"11","author":"Sun","year":"2022","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.jare.2025.04.029_b0115","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41569-023-00957-0","article-title":"Programmed death of macrophages in atherosclerosis: mechanisms and therapeutic targets","volume":"21","author":"De Meyer","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jare.2025.04.029_b0120","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00109-017-1575-8","article-title":"Mechanisms of foam cell formation in atherosclerosis","volume":"95","author":"Chistiakov","year":"2017","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.jare.2025.04.029_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155527","article-title":"TNF\u03b1-induced NLRP3 inflammasome mediates adipocyte dysfunction and activates macrophages through adipocyte-derived lipocalin 2","volume":"142","author":"Javaid","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.jare.2025.04.029_b0130","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s12967-023-04270-9","article-title":"Inhibition of DRP1-dependent mitochondrial fission by Mdivi-1 alleviates atherosclerosis through the modulation of M1 polarization","volume":"21","author":"Su","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.jare.2025.04.029_b0135","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154217","article-title":"Disruption of USP9X in macrophages promotes foam cell formation and atherosclerosis","volume":"132","author":"Wang","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jare.2025.04.029_b0140","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1161\/ATVBAHA.123.320612","article-title":"Macrophage-derived GSDMD plays an essential role in atherosclerosis and cross talk between macrophages via the mitochondria-STING-IRF3\/NF-\u03baB axis","volume":"44","author":"Fan","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jare.2025.04.029_b0145","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/jre.13196","article-title":"Interleukin-37 ameliorates periodontitis development by inhibiting NLRP3 inflammasome activation and modulating M1\/M2 macrophage polarization","volume":"59","author":"Yang","year":"2024","journal-title":"J Periodontal Res"},{"key":"10.1016\/j.jare.2025.04.029_b0150","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1038\/s41423-020-00567-7","article-title":"USP19 suppresses inflammation and promotes M2-like macrophage polarization by manipulating NLRP3 function via autophagy","volume":"18","author":"Liu","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jare.2025.04.029_b0155","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1124\/pharmrev.122.000629","article-title":"Pharmacological inhibition of the NLRP3 inflammasome: structure, molecular activation, and inhibitor-NLRP3 interaction","volume":"75","author":"Ma","year":"2023","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jare.2025.04.029_b0160","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41423-021-00670-3","article-title":"An update on the regulatory mechanisms of NLRP3 inflammasome activation","volume":"18","author":"Paik","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jare.2025.04.029_b0165","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.tibs.2022.10.002","article-title":"The NLRP3 inflammasome: activation and regulation","volume":"48","author":"Xu","year":"2023","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.jare.2025.04.029_b0170","article-title":"The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors","volume":"13","author":"Zhan","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jare.2025.04.029_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109312","article-title":"Resibufogenin, one of bufadienolides in toad venom, suppresses LPS-induced inflammation via inhibiting NF-\u03baB and AP-1 pathways","volume":"113","author":"Gao","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jare.2025.04.029_b0180","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s12967-018-1580-x","article-title":"Resibufogenin suppresses colorectal cancer growth and metastasis through RIP3-mediated necroptosis","volume":"16","author":"Han","year":"2018","journal-title":"J Transl Med"},{"key":"10.1016\/j.jare.2025.04.029_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111581","article-title":"Analysis of resibufogenin on cardiac conduction reveals a species difference in the cardiac electrophysiology: rats versus guinea pigs","volume":"139","author":"Song","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jare.2025.04.029_b0190","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s10522-023-10043-0","article-title":"Identification of resibufogenin, a component of toad venom, as a novel senolytic compound in vitro and for potential skin rejuvenation in male mice","volume":"24","author":"Takaya","year":"2023","journal-title":"Biogerontology"},{"key":"10.1016\/j.jare.2025.04.029_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2019.152971","article-title":"Simultaneous determination of resibufogenin and its eight metabolites in rat plasma by LC-MS\/MS for metabolic profiles and pharmacokinetic study","volume":"60","author":"Wei","year":"2019","journal-title":"Phytomedicine"},{"key":"10.1016\/j.jare.2025.04.029_b0200","first-page":"169","article-title":"DH. [Effects of resibufogenin on the action potential of myocardial fibers of the dog and guinea pig]","volume":"6","author":"Xie","year":"1985","journal-title":"Zhongguo Yao Li Xue Bao"},{"key":"10.1016\/j.jare.2025.04.029_b0205","article-title":"Resibufogenin suppresses triple-negative breast cancer angiogenesis by blocking VEGFR2-mediated signaling pathway","volume":"12","author":"Yang","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jare.2025.04.029_b0210","doi-asserted-by":"crossref","DOI":"10.1021\/acs.orglett.4c03433","article-title":"Scalable Protecting-group-free total synthesis of resibufogenin and bufalin","author":"Yu","year":"2024","journal-title":"Org Lett"},{"key":"10.1016\/j.jare.2025.04.029_b0215","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3892\/etm.2022.11368","article-title":"Resibufogenin inhibits the malignant characteristics of multiple myeloma cells by blocking the PI3K\/Akt signaling pathway","volume":"24","author":"Zhou","year":"2022","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.jare.2025.04.029_b0220","article-title":"Resibufogenin targets the ATP1A1 signaling cascade to induce G2\/M phase arrest and inhibit invasion in glioma","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jare.2025.04.029_b0225","unstructured":"ZL X. Study on the Inhibitory Effect of Resibufogenin, an active ingredient in bufonis, on LPS induced macrophage inflammation [D]. Peking Union Medical College, 2023. doi: 10.27648\/d.cnki.gzxhu.2023.000732."},{"key":"10.1016\/j.jare.2025.04.029_b0230","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000108756","article-title":"Effects of resibufogenin in experimental hypertension","volume":"28","author":"Danchuk","year":"2008","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jare.2025.04.029_b0235","article-title":"Resibufogenin: an emerging therapeutic compound with multifaceted pharmacological effects - a comprehensive review","volume":"30","author":"Zhang","year":"2024","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.jare.2025.04.029_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102404","article-title":"Inhibition of NLRP3-mediated crosstalk between hepatocytes and liver macrophages by geniposidic acid alleviates cholestatic liver inflammatory injury","volume":"55","author":"Song","year":"2022","journal-title":"Redox Biol"},{"key":"10.1016\/j.jare.2025.04.029_b0245","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejvs.2022.04.011","article-title":"Editor's Choice - European society for vascular surgery (ESVS) 2023 clinical practice guidelines on the management of atherosclerotic carotid and vertebral artery disease","volume":"65","author":"Naylor","year":"2023","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jare.2025.04.029_b0250","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease","volume":"82","author":"Virani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jare.2025.04.029_b0255","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.jacc.2023.09.817","article-title":"Primary prevention of subclinical atherosclerosis in young adults: JACC review topic of the week","volume":"82","author":"Devesa","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jare.2025.04.029_b0260","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jcmg.2022.06.018","article-title":"Major global coronary artery calcium guidelines","volume":"16","author":"Golub","year":"2023","journal-title":"J Am Coll Cardiol Img"},{"key":"10.1016\/j.jare.2025.04.029_b0265","first-page":"149","article-title":"ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"2024","author":"Gornik","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jare.2025.04.029_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103345","article-title":"High expression levels of haem oxygenase-1 promote ferroptosis in macrophage-derived foam cells and exacerbate plaque instability","volume":"76","author":"Guo","year":"2024","journal-title":"Redox Biol"},{"key":"10.1016\/j.jare.2025.04.029_b0275","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1038\/s41467-018-04947-6","article-title":"Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity","volume":"9","author":"He","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jare.2025.04.029_b0280","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41419-023-06206-z","article-title":"Macrophage polarization and metabolism in atherosclerosis","volume":"14","author":"Hou","year":"2023","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jare.2025.04.029_b0285","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1021\/acs.jmedchem.0c01307","article-title":"Strategies for targeting the NLRP3 inflammasome in the clinical and preclinical space","volume":"64","author":"Schwaid","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.jare.2025.04.029_b0290","first-page":"289","article-title":"Cardiac toxicity of resibufogenin: electrophysiological evidence","volume":"22","author":"Xie","year":"2001","journal-title":"Acta Pharmacol Sin"}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123225002723?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123225002723?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T01:18:26Z","timestamp":1769822306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2090123225002723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":58,"alternative-id":["S2090123225002723"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2025.04.029","relation":{},"ISSN":["2090-1232"],"issn-type":[{"value":"2090-1232","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resibufogenin protects against atherosclerosis in ApoE-\/- mice through blocking NLRP3 inflammasome assembly","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2025.04.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Cairo University.","name":"copyright","label":"Copyright"}]}}